• Sep 15, 2026

  $143.79-0.73%

• Sep 14, 2026

  $144.85+0.64%

  Merck entered a clinical collaboration and supply agreement with Perspective Therapeutics to evaluate a combination therapy with Keytruda in solid tumors [1]. Comparable pharmaceutical companies rose 1.00% on average that day, with all six peers gaining, a smaller move than Merck's own increase [2].

  • 1Globenewswire
  • 2Peer group

• Sep 11, 2026

  $143.93-0.54%

• Sep 10, 2026

  $144.71-1.91%

  Comparable pharmaceutical companies fell 0.34% on average, with MRK's decline outpacing that peer move [1].

  • 1Peer group

• Sep 9, 2026

  $147.53-0.63%

• Sep 8, 2026

  $148.46-1.24%

  Comparable pharmaceutical preparations companies fell 2.74% on average the same day, with all six names lower [1].

  • 1Peer group

• Sep 4, 2026

  $150.33-1.32%

  MRK shares fell 1.32%, in line with comparable pharmaceutical preparations companies, which moved -1.38% on average as all six tracked peers declined [1]. Trading volume was light, at 0.4x the trailing average, with the session ranging between 150.09 and 152.22 [2].

  • 1Peer group
  • 2Market data

Closing prices for MRK. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.